JP2025529240A - トリナパント、セダズリジン及びデシタビンによるt細胞リンパ腫の治療のための併用療法 - Google Patents
トリナパント、セダズリジン及びデシタビンによるt細胞リンパ腫の治療のための併用療法Info
- Publication number
- JP2025529240A JP2025529240A JP2025513127A JP2025513127A JP2025529240A JP 2025529240 A JP2025529240 A JP 2025529240A JP 2025513127 A JP2025513127 A JP 2025513127A JP 2025513127 A JP2025513127 A JP 2025513127A JP 2025529240 A JP2025529240 A JP 2025529240A
- Authority
- JP
- Japan
- Prior art keywords
- cell lymphoma
- decitabine
- trinapant
- lymphoma
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263374137P | 2022-08-31 | 2022-08-31 | |
| US63/374,137 | 2022-08-31 | ||
| PCT/IB2022/060652 WO2024047394A1 (en) | 2022-08-31 | 2022-11-04 | Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025529240A true JP2025529240A (ja) | 2025-09-04 |
| JP2025529240A5 JP2025529240A5 (cg-RX-API-DMAC7.html) | 2025-11-05 |
Family
ID=84359488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025513127A Pending JP2025529240A (ja) | 2022-08-31 | 2022-11-04 | トリナパント、セダズリジン及びデシタビンによるt細胞リンパ腫の治療のための併用療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240082286A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4580635A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025529240A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250053870A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022476674A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3266274A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2025002312A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202410893A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2024047394A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115368356B (zh) | 2013-12-20 | 2025-05-09 | 阿斯特克斯治疗有限公司 | 双环杂环化合物及其治疗用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| JO2778B1 (en) | 2007-10-16 | 2014-03-15 | ايساي انك | Certain Compounds, Compositions and Methods |
| CN115368356B (zh) | 2013-12-20 | 2025-05-09 | 阿斯特克斯治疗有限公司 | 双环杂环化合物及其治疗用途 |
| LT4069254T (lt) * | 2020-02-25 | 2024-10-10 | Otsuka Pharmaceutical Co., Ltd. | Kietos geriamosios vaisto formos, apimančios decitabiną ir cedazuridiną |
-
2022
- 2022-11-04 JP JP2025513127A patent/JP2025529240A/ja active Pending
- 2022-11-04 TW TW111142283A patent/TW202410893A/zh unknown
- 2022-11-04 AU AU2022476674A patent/AU2022476674A1/en active Pending
- 2022-11-04 KR KR1020257007164A patent/KR20250053870A/ko active Pending
- 2022-11-04 CA CA3266274A patent/CA3266274A1/en active Pending
- 2022-11-04 WO PCT/IB2022/060652 patent/WO2024047394A1/en not_active Ceased
- 2022-11-04 EP EP22805975.4A patent/EP4580635A1/en active Pending
-
2023
- 2023-08-30 US US18/458,884 patent/US20240082286A1/en active Pending
-
2025
- 2025-02-26 MX MX2025002312A patent/MX2025002312A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4580635A1 (en) | 2025-07-09 |
| WO2024047394A1 (en) | 2024-03-07 |
| AU2022476674A1 (en) | 2025-04-17 |
| MX2025002312A (es) | 2025-04-02 |
| KR20250053870A (ko) | 2025-04-22 |
| TW202410893A (zh) | 2024-03-16 |
| US20240082286A1 (en) | 2024-03-14 |
| CA3266274A1 (en) | 2024-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230364086A1 (en) | Combination therapies with ehmt2 inhibitors | |
| US10537580B2 (en) | Azocane and azonane derivatives and methods of treating hepatitis B infections | |
| US11149011B2 (en) | Compounds and methods for IDO and TDO modulation, and indications therefor | |
| JP2017531619A5 (cg-RX-API-DMAC7.html) | ||
| US20240165116A1 (en) | Rock2 inhibitor for the treatment of viral infection | |
| EP2906564B1 (en) | Treating brain cancer using agelastatin a (aa) and analogues thereof | |
| CN107108557A (zh) | 用于治疗和预防呼吸道合胞体病毒(rsv)感染的螺环二氢吲哚类 | |
| WO2022256529A1 (en) | Compounds for treating nash and nafld | |
| TW202545959A (zh) | 用於治療病毒感染的化合物及方法 | |
| WO2020117966A1 (en) | Highly active drug combination for treatment of hepatitis c virus | |
| TWI857018B (zh) | 2'3'-環二核苷酸及其前藥 | |
| US20240082286A1 (en) | Combination therapies for treatment of t-cell lymphomas | |
| US20210369715A1 (en) | Novel uses | |
| US20250186451A1 (en) | Methods of treating cancer with iap antagonist compounds and combination therapies | |
| JP2022130716A (ja) | IRAK4阻害剤としてのピロロ[1,2-b]ピリダジン誘導体 | |
| US20200048261A1 (en) | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | |
| AU2018379230A1 (en) | Treatment of RSV with combination product | |
| JP7337539B2 (ja) | 白血病療法のための塩基修飾シチジンヌクレオチド | |
| US20240041854A1 (en) | Cold medicine and antiviral medicine | |
| HK40113957A (en) | Methods for treating sars cov-2 infections | |
| HK40111613A (en) | Compounds and methods for treatment of viral infections | |
| JP2023139233A5 (cg-RX-API-DMAC7.html) | ||
| HK40057712B (en) | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition and uses thereof | |
| EA045798B1 (ru) | Замещенные соединения 6-азабензимидазола | |
| BR102018002879A2 (pt) | composto, e, método para tratamento de uma doença ou distúrbio relacionado com a inflamação em um paciente em necessidade do mesmo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251024 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251024 |